{"entity": "publication", "iuid": "2f16e19f50e84f20af1f23f998bc1e04", "timestamp": "2026-09-26T23:46:15.830Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/2f16e19f50e84f20af1f23f998bc1e04.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/2f16e19f50e84f20af1f23f998bc1e04"}}, "title": "Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting.", "authors": [{"family": "Nilsson", "given": "Christer", "initials": "C"}, {"family": "Huleg\u00e5rdh", "given": "Erik", "initials": "E"}, {"family": "Garelius", "given": "Hege", "initials": "H"}, {"family": "M\u00f6llg\u00e5rd", "given": "Lars", "initials": "L"}, {"family": "Brune", "given": "Mats", "initials": "M"}, {"family": "Wahlin", "given": "Anders", "initials": "A"}, {"family": "Lenhoff", "given": "Stig", "initials": "S"}, {"family": "Fr\u00f6din", "given": "Ulla", "initials": "U"}, {"family": "Remberger", "given": "Mats", "initials": "M"}, {"family": "H\u00f6glund", "given": "Martin", "initials": "M"}, {"family": "Juliusson", "given": "Gunnar", "initials": "G"}, {"family": "Stockelberg", "given": "Dick", "initials": "D"}, {"family": "Lehmann", "given": "S\u00f6ren", "initials": "S"}], "type": "journal article", "published": "2019-09-00", "journal": {"title": "Biol Blood Marrow Transplant", "issn": "1523-6536", "volume": "25", "issue": "9", "pages": "1770-1778", "issn-l": null}, "abstract": "Secondary AML (s-AML), including AML with an antecedent hematologic disorder (AHD-AML) and therapy-related AML (t-AML), constitutes a large proportion of patients with AML and is considered to confer a dismal prognosis. The role of allogeneic hematopoietic cell transplantation (HCT) in patients with s-AML and the extent to which HCT is performed in these patients has been little studied to date. We used the population-based Swedish AML Registry comprising 3337 intensively treated adult patients over a 17-year period to study the role of HCT within the group of patients with s-AML as well as compared with patients with de novo AML. HCT was performed in 576 patients (22%) with de novo AML, in 74 patients (17%) with AHD-AML, and in 57 patients (20%) with t-AML. At 5 years after diagnosis, there were no survivors among patients with previous myeloproliferative neoplasms who did not undergo HCT, and corresponding survival for patients with antecedent myelodysplastic syndromes and t-AML was and 2% and 4%, respectively. HCT was compared with chemotherapy consolidation in s-AML using 3 models: (1) a 200-day landmark analysis, in which HCT was favorable compared with conventional consolidation (P = .04, log-rank test); (2) a multivariable Cox regression with HCT as a time-dependent variable, in which the hazard ratio for mortality was 0.73 (95% confidence interval, 0.64 to 0.83) for HCT and favored HCT in all subgroups; and (3) a propensity score matching analysis, in which the 5-year overall survival (OS) and relapse-free survival in patients with s-AML in first complete remission (CR1) was 48% and 43%, respectively, for patients undergoing HCT versus 20% and 21%, respectively, for those receiving chemotherapy consolidation (P = .01 and .02, respectively, log-rank test). Our observational data suggest that HCT improves survival and offers the only realistic curative treatment option in patients with s-AML.", "doi": "10.1016/j.bbmt.2019.05.038", "pmid": "31176789", "labels": [], "xrefs": [{"db": "pii", "key": "S1083-8791(19)30363-5"}], "notes": [], "created": "2026-09-23T09:44:16.795Z", "modified": "2026-09-23T10:18:33.287Z"}